Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-m9kch Total loading time: 0 Render date: 2024-05-16T03:40:05.627Z Has data issue: false hasContentIssue false

25 - Immunotherapy and Recurrent Pregnancy Loss

Published online by Cambridge University Press:  16 February 2017

By
Anita Kuriya  and
William M. Buckett
Edited by
Roy G. Farquharson  and
Mary D. Stephenson
Roy G. Farquharson
Affiliation:
Liverpool Women's Hospital
Mary D. Stephenson
Affiliation:
University of Illinois College of Medicine
Get access
Type
Chapter
Information
Early Pregnancy , pp. 247 - 255
Publisher: Cambridge University Press
Print publication year: 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Dosiou, C, Giudice, LC. Natural killer cells in pregnancy and recurrent pregnancy loss: endocrine and immunologic perspectives. Endocrine Rev 2005;26(1):44–62.CrossRefGoogle ScholarPubMed
Coulam, CB, Stephenson, M, Stern, JJ, Clark, DA. Immunotherapy for recurrent pregnancy loss: analysis of results from clinical trials. Am J Reprod Immunol 1996;35(4):352–59.CrossRefGoogle ScholarPubMed
Kotlan, B, Padanyi, A, Batorfi, J, Fulop, V, Szigetvari, I, Rajczy, K, et al. Alloimmune and autoimmune background in recurrent pregnancy loss – successful immunotherapy by intravenous immunoglobulin. Am J Reprod Immunol 2006;55(5):331–40.CrossRefGoogle ScholarPubMed
Wong, LF, Porter, TF, Scott, JR. Immunotherapy for recurrent miscarriage. The Cochrane Database of Systematic Reviews. 2014;10: CD000112.Google Scholar
Porter, TF, LaCoursiere, Y, Scott, JR. Immunotherapy for recurrent miscarriage. The Cochrane Database of Systematic Reviews. 2006;2:CD000112.CrossRefGoogle Scholar
Leber, A, Teles, A, Zenclussen, AC. Regulatory T cells and their role in pregnancy. Am J Reprod Immunol 2010;63(6):445–59.CrossRefGoogle ScholarPubMed
Guerin, LR, Prins, JR, Robertson, SA. Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? Hum Reprod Update 2009;15(5):517–35.CrossRefGoogle ScholarPubMed
Mowbray, JF, Gibbings, C, Liddell, H, Reginald, PW, Underwood, JL, Beard, RW. Controlled trial of treatment of recurrent spontaneous abortion by immunisation with paternal cells. Lancet 1985;1:941–43.Google ScholarPubMed
Moffat, A, Shreeve, N. First do no harm: uterine natural killer (NK) cells in assisted reproduction. Hum Reprod 2015; 30: 1519–25.Google Scholar
Karrison, TG, Ober, C. Recurrent miscarriage (REMIS) study: how should data from women who do not become pregnant be handled? Controlled Clinical Trials 1998;19(5):430–39.Google Scholar
Pandey, MK, Thakur, S, Agrawal, S. Lymphocyte immunotherapy and its probable mechanism in the maintenance of pregnancy in women with recurrent spontaneous abortion. Arch Gynecol Obstet 2004;269(3):161–72.CrossRefGoogle ScholarPubMed
Illeni, MT, Marelli, G, Parazzini, F, Acaia, B, Bocciolone, L, Bontempelli, M, et al. Immunotherapy and recurrent abortion: a randomized clinical trial. Hum Reprod 1994;9(7):1247–49.CrossRefGoogle ScholarPubMed
Ober, C, Karrison, T, Odem, RR, Barnes, RB, Branch, DW, Stephenson, MD, et al. Mononuclear-cell immunisation in prevention of recurrent miscarriages: a randomised trial. Lancet 1999;354(9176):365–69.Google Scholar
Coulam, CB, Coulam, CH. Update on immunotherapy for recurrent pregnancy loss. Am J Reprod Immunol 1992;27(3–4):124–27.CrossRefGoogle ScholarPubMed
Auclair, JM. Corticoid therapy in habitual abortions. Clinique (Paris) 1965;60(612):671–72.Google Scholar
Hartikainen-Sorri, AL, Kaila, J. Systemic lupus erythematosus and habitual abortion. Case report. Br J Obstet Gynaecol 1980;87(8):729–31.CrossRefGoogle ScholarPubMed
Gancel, A, Courtois, H, Doucet, J, Schrub, JC. Multiple fetal losses caused by a circulating anticoagulant. Correction with a combination of aspirin and corticotherapy. Presse Med 1986;15(30):1426–27.Google Scholar
Quenby, S, Nik, H, Innes, B, Lash, G, Turner, M, Drury, J, et al. Uterine natural killer cells and angiogenesis in recurrent reproductive failure. Hum Reprod 2009;24(1):45–54.Google Scholar
Hanna, J, Goldman-Wohl, D, Hamani, Y, Avraham, I, Greenfield, C, Natanson-Yaron, S, et al. Decidual NK cells regulate key developmental processes at the human fetal–maternal interface. Nature Med 2006;12(9):1065–74.CrossRefGoogle ScholarPubMed
Tang, AW, Alfirevic, Z, Turner, MA, Drury, JA, Small, R, Quenby, S. A feasibility trial of screening women with idiopathic recurrent miscarriage for high uterine natural killer cell density and randomizing to prednisolone or placebo when pregnant. Hum Reprod 2013;28(7):1743–52.Google Scholar
Quenby, S, Kalumbi, C, Bates, M, Farquharson, R, Vince, G. Prednisolone reduces preconceptual endometrial natural killer cells in women with recurrent miscarriage. Fertil Steril 2005;84(4):980–84.Google Scholar
Hiby, SE, Regan, L, Lo, W, Farrell, L, Carrington, M, Moffett, A. Association of maternal killer-cell immunoglobulin-like receptors and parental HLA-C genotypes with recurrent miscarriage. Hum Reprod 2008;23(4):972–76.Google Scholar
Gomaa, MF, Elkholy, AG, El-Said, MM, Abdel-Salam, NE. Combined oral prednisolone and heparin versus heparin: the effect on peripheral NK cells and clinical outcome in patients with unexplained recurrent miscarriage. A double-blind placebo randomized controlled trial. Arch Gynecol Obstet 2014;290(4):757–62.Google Scholar
Christiansen, O, Larsen, E, Egerup, P, Lunoee, L, Egestad, L, Nielsen, H. Intravenous immunoglobulin treatment for secondary recurrent miscarriage: a randomised, double-blind, placebo-controlled trial. Br J Obstet Gynaecol 2015 Mar;122(4):500–08.CrossRefGoogle ScholarPubMed
Sapir, T, Blank, M, Shoenfeld, Y. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann NY Acad Sci 2005;1051:743–78.CrossRefGoogle ScholarPubMed
Department of Health (DoH). Clinical guidelines for immunoglobulin use. 2011. http://www.ivig.nhs.uk/documents/dh_129666.pdf.Google Scholar
Mueller-Eckhardt, G, Heine, O, Polten, B. IVIG to prevent recurrent spontaneous abortion. Lancet 1991;337(8738):424–25.Google Scholar
The German RSA/IVIG Group. Intravenous immunoglobulin in the prevention of recurrent miscarriage. Br J Obstet Gynaecol 1994;101(12):1072–77.Google Scholar
Christiansen, OB, Mathiesen, O, Husth, M, Rasmussen, KL, Ingerslev, HJ, Lauritsen, JG, et al. Placebo-controlled trial of treatment of unexplained secondary recurrent spontaneous abortions and recurrent late spontaneous abortions with I.V. immunoglobulin. Hum Reprod 1995;10(10):2690–95.CrossRefGoogle ScholarPubMed
Coulam, CB, Krysa, L, Stern, JJ, Bustillo, M. Intravenous immunoglobulin for treatment of recurrent pregnancy loss. Am J Reprod Immunol 1995;34(6):333–37.Google Scholar
Perino, A, Vassiliadis, A, Vucetich, A, Colacurci, N, Menato, G, Cignitti, M, et al. Short-term therapy for recurrent abortion using intravenous immunoglobulins: results of a double-blind placebo-controlled Italian study. Hum Reprod 1997;12(11):2388–92.CrossRefGoogle ScholarPubMed
Ata, B, Tan, SL, Shehata, F, Holzer, H, Buckett, W. A systematic review of intravenous immunoglobulin for treatment of unexplained recurrent miscarriage. Fertil Steril 2011;95(3):1080–85.Google Scholar
Stephenson, MD, Kutteh, WH, Purkiss, S, Librach, C, Schultz, P, Houlihan, E, et al. Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial. Hum Reprod 2010;25(9):2203–09.CrossRefGoogle ScholarPubMed
Stephenson, MD, Dreher, K, Houlihan, E, Wu, V. Prevention of unexplained recurrent spontaneous abortion using intravenous immunoglobulin: a prospective, randomized, double-blinded, placebo-controlled trial. Am J Reprod Immunol 1998;39(2):82–88.CrossRefGoogle ScholarPubMed
Christiansen, OB, Pedersen, B, Rosgaard, A, Husth, M. A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage. Hum Reprod 2002;17(3):809–16.Google Scholar
Hutton, B, Sharma, R, Fergusson, D, Tinmouth, A, Hebert, P, Jamieson, J, et al. Use of intravenous immunoglobulin for treatment of recurrent miscarriage: a systematic review. Br J Obstet Gynaecol 2007;114(2):134–42.Google Scholar
Christiansen, O, Larsen, E, Egerup, P, Lunoee, L, Egestad, L, Nielsen, H. Intravenous immunoglobulin treatment for secondary recurrent miscarriage: a randomised, double-blind, placebo-controlled trial. Br J Obstet Gynaecol 2015;122(4):500–08.Google Scholar
Yamada, H, Deguchi, M, Maesawa, Y, Nakajima, Y, Nishino, Y, Tanimura, K, et al. Medium-dose intravenous immunoglobulin therapy for women with six or more recurrent miscarriages. J Reprod Immunol 2015;109:48–51.CrossRefGoogle ScholarPubMed
Duhem, C, Dicato, MA, Ries, F. Side-effects of intravenous immune globulins. Clin Exp Immunol 1994;97 (Suppl 1):79–83.Google Scholar
Driver, I, Feather, JW, King, PR, Dawson, JB. The optical properties of aqueous suspensions of intralipid, a fat emulsion. Phys Med Biol 1989; 34(12):1927–30.CrossRefGoogle Scholar
Granato, D, Blum, S, Rössle, C, Le Boucher, J, Malnoë, A, Dutot, G. Effects of parenteral lipid emulsions with different fatty acid composition on immune cell functions in vitro. J Parenter Enter Nutr 2000;24(2):113–18.Google Scholar
Bin, L, Wang, S, Ye, YJ, Yang, XD, Wang, YL, Qu, J, et al. Impact of postoperative omega-3 fatty acid-supplemented parenteral nutrition on clinical outcomes and immunomodulations in colorectal cancer patients. World J Gastroenterol 2008; 14(15):2434–39.Google Scholar
Clark, DA. Intralipid as treatment for recurrent unexplained abortion? Am J Reprod Immunol 1994;32(4):290–93.CrossRefGoogle ScholarPubMed
Coulam, CB, Acacio, B. Does immunotherapy for treatment of reproductive failure enhance live births? Am J Reprod Immunol 2012; 67:296–304.CrossRefGoogle ScholarPubMed
Tartakovsky, B, Ben-Yair, E. Cytokines modulate preimplantation development and pregnancy. Dev Biol 1991;146:345–52.Google Scholar
Imseis, HM, Zimmerman, PD, Samuels, P, Kniss, DA. Tumour necrosis factor-alpha induces cyclo-oxygenase-2 gene expression in first trimester trophoblasts: suppression by glucocorticoids and NSAIDs. Placenta 1997;18:521–26.Google Scholar
Daher, S, Fonseca, F, Ribeiro, OG, Musatti, CC, Gerbase-DeLima, M. Tumor necrosis factor during pregnancy and at the onset of labor and spontaneous abortion. Eur J Obstet Gynecol Reprod Biol 1999;83:77–79.Google Scholar
Yu, XW, Yan, CF, Jin, H, Li, X. Tumor necrosis factor receptor 1 expression and early spontaneous abortion. Int J Gynaecol Obstet 2005;88:44–48.CrossRefGoogle ScholarPubMed
Clowse, MEB. The use of anti-TNFα medications for rheumatologic disease in pregnancy. Int J Womens Health 2010;2:199–209.CrossRefGoogle ScholarPubMed
Marchioni, RM, Lichtenstein, GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol 2013; 19(17):2591–602.CrossRefGoogle ScholarPubMed
Winger, EE, Reed, JL. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol 2008;60(1):8–16.Google Scholar
Shorter, SC, Vince, GS, Starkey, PM. Production of granulocyte colony-stimulating factor at the materno-foetal interface in human pregnancy. Immunology 1992;75:468–74.Google Scholar
McCracken, SA, Grant, KE, MacKenzie, IZ, Redman, CW, Mardon, HJ. Gestational regulation of granulocyte-colony stimulating factor receptor expression in the human placenta. Biol Reprod 1999;60:790–96.Google Scholar
Sugita, K, Hayakawa, S, Karasaki-Suzuki, M, Hagiwara, H, Chishima, F, Aleemuzaman, S, et al. Granulocyte colony stimulation factor (G-CSF) suppresses interleukin (IL)-12 and/or IL-2 induced interferon (IFN)-gamma production and cytotoxicity of decidual mononuclear cells. Am J Reprod Immunol 2003;50:83–89.CrossRefGoogle ScholarPubMed
Litwin, S, Lagadari, M, Barrientos, G, Roux, ME, Margni, R, Miranda, S. Comparative immunohistochemical study of M-CSF and G-CSF in feto-maternal interface in a multiparity mouse model. Am J Reprod Immunol 2005;54:311–20.Google Scholar
Scarpellini, F, Sbracia, M. Use of granulocyte colony-stimulating factor for the treatment of unexplained recurrent miscarriage: a randomised controlled trial. Hum Reprod 2009;24:2703–08.CrossRefGoogle ScholarPubMed
Santjohanser, C, Knieper, C, Franz, C, Hirv, K, Meri, O, Schleyer, M, et al. Granulocyte-colony stimulating factor as treatment option in patients with recurrent miscarriage. Arch Immunol Ther Exp (Warsz) 2013;61:159–64.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×